Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
Swiss pharma hopes to bounce back from Q1 sales disappointment
Richard Staines
AbbVie, ankylosing spondylitis, Cosentyx, EULAR, Novartis, psoriatic arthritis, rheumatology
0 Comment
Swiss pharma hopes to bounce back from Q1 sales disappointment
Richard Staines
arthritis, Celgene, cost-effectiveness, NICE, rheumatology
0 Comment
Otezla cheap and convenient, but less effective than rivals, says NICE.
Richard Staines
EULAR, GSK, Janssen, Rheumatoid arthritis, rheumatology
0 Comment
R-Pharm has a mid-stage rival.
Richard Staines
Biogen, biosimilars, Biotech, Humira, market access, Rheumatoid arthritis, rheumatology
0 Comment
Gamble on opicinumab looks unlikely to pay off.
Richard Staines
arthritis, biosimilar, EULAR, immunology, inflammation, Rheumatoid arthritis, rheumatology, UK
0 Comment
But attendees warned to expect “oceanic” weather.